
    
      This is a randomized, double-blinded study of three doses of MSDC-0602K or placebo given
      orally once daily to subjects with biopsy proven NASH with fibrosis and no cirrhosis. Visits
      to the clinic will be at baseline, 1, 2, 3, 6, 9, and 12 months, with one 2- week follow-up
      visit.

      Safety will be assessed by monitoring of vital signs, 12 lead electrocardiogram (ECG),
      physical examinations, safety labs, and adverse events (AEs).
    
  